About
Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders. The company has created a digital therapeutics platform of clinically proven neuromodulation-based solutions that can be delivered to patients at home or in the community. Neuroliefs Relivion is a noninvasive multichannel brain neuromodulation system for treating neurological and neuropsychiatric disorders. It offers precise, personalized care by delivering stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This creates a cumulative effect by releasing neurotransmitters in the brainstem to modulate the brain networks associated with pain and mood control. The Relivion device is placed comfortably on the patients head, where it stimulates the nerves. The connected e-Relief mobile app displays the treatment status and transmits information between the patient and the cloud. The Relivion system is FDA approved and CE marked and has been granted breakthrough device designation by the FDA.
Funding history · 4 rounds · $17.1M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Neurolief's primary focus in terms of medical treatment?
- Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders, utilizing a digital therapeutics platform of neuromodulation-based solutions.
- When was Neurolief founded and where is its headquarters located?
- Neurolief was founded in August 2013 and is headquartered in Netanya, Israel.
- What is the name of Neurolief's core product and what is its function?
- Neurolief's core product is Relivion, a noninvasive multichannel brain neuromodulation system designed for treating neurological and neuropsychiatric disorders, including migraine and depression.
- What significant regulatory approvals has Neurolief's Relivion system received?
- The Relivion system is FDA approved and CE marked. It has also been granted breakthrough device designation by the FDA.
- Which company made a strategic investment in Neurolief in August 2025?
- In August 2025, Brainsway invested $5 million in Neurolief to expand its mental health care market.
- What was a key operational development for Neurolief in January 2021?
- In January 2021, Neurolief announced positive results from its RIME Clinical Study for its brain neuromodulation system for treating acute migraine.
- What significant FDA approval did Neurolief receive in January 2026?
- In January 2026, Neurolief received FDA PMA approval for the first at-home brain neuromodulation therapy for adults whose depression was not adequately improved by antidepressants.
- Which markets did Neurolief expand into through a licensing agreement in July 2021?
- In July 2021, Neurolief announced an exclusive licensing agreement with NeuroFront for the development and commercialization of Relivion® in Greater China and South Korea.
- How many employees does Neurolief currently have?
- Neurolief currently has 28 employees, falling within the 11-50 employee bucket.